← FDA DRUG APPROVALS

FDA ANDA · ANDA078688

NADOLOL AND BENDROFLUMETHIAZIDE

Sponsor: NATCO PHARMA

APPLICATION
ANDA078688
TYPE
ANDA
ORIGINAL APPROVAL
2008-02-15
LATEST ACTION
2008-02-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NADOLOL AND BENDROFLUMETHIAZIDEDiscontinued
BENDROFLUMETHIAZIDE 5MG, NADOLOL 40MG · TABLET · ORAL
NADOLOL AND BENDROFLUMETHIAZIDEDiscontinued
BENDROFLUMETHIAZIDE 5MG, NADOLOL 80MG · TABLET · ORAL

Approval history

2008-02-15OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →